Ozempic vs Wegovy UK: Clinical Evidence & Weight Loss

Clinically Proven UK Registered Pharmacy

Ozempic vs Wegovy UK - Cheapest Price From £69.00

Compare Ozempic and Wegovy at the cheapest UK price from £69, plus get £20 off your first order with code WEIGHTLOSSNEW.

UK-registered clinical team
Confidential and secure
No GP visit needed
Fast and discreet delivery
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off first order using code WEIGHTLOSSNEW
Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment
£89.00 From £69.00 £10 discount using discount code Weightlossnew
LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£99 £79.00

£19.75 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £99
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation

Ozempic vs Wegovy: Clinical Evidence & UK Weight Loss Data

Understanding ozempic vs wegovy uk weight loss options requires examining clinical trial evidence and regulatory approval differences. Both medications contain semaglutide, but Wegovy is specifically licensed by the MHRA for chronic weight management, whilst Ozempic holds approval solely for type 2 diabetes treatment. At Cured Pharmacy, our UK-registered clinical team helps patients access appropriate semaglutide treatment following comprehensive assessment.

Understanding Semaglutide: The Active Ingredient in Both Medications

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics a naturally occurring hormone in your body. This medication works by slowing gastric emptying, reducing appetite signals to the brain, and improving insulin secretion in response to meals [1]. Both Ozempic and Wegovy contain this identical active pharmaceutical ingredient, yet they differ significantly in their licensed indications and dosing protocols.

The mechanism of action remains consistent across both formulations: semaglutide binds to GLP-1 receptors in multiple tissues, including the pancreas, brain, and gastrointestinal tract. Clinical research demonstrates that this multi-system approach produces sustained appetite reduction and improved metabolic control, making semaglutide one of the most effective pharmacological interventions for weight management currently available in the UK [1][2].

Ozempic vs Wegovy UK: Regulatory Approval and Licensed Indications

The regulatory distinction reflects different clinical development programmes and trial endpoints. Ozempic's approval relied on cardiovascular and glycaemic control data from the SUSTAIN trials, whilst Wegovy's licensing drew upon the STEP (Semaglutide Treatment Effect in People with obesity) programme, which specifically evaluated weight loss outcomes [2][3]. UK prescribers must consider these regulatory frameworks when determining appropriate treatment pathways.

NICE guidance currently recommends specialist weight management services consider GLP-1 receptor agonists like Wegovy for eligible patients, subject to specific criteria including previous lifestyle intervention attempts and ongoing dietary support [4]. This structured approach ensures patients receive comprehensive care rather than medication alone.

MHRA Licensing Differences

Ozempic received MHRA approval in 2018 for treating type 2 diabetes mellitus in adults, with doses ranging from 0.25mg to 2mg weekly. Wegovy gained separate UK licensing in September 2021 specifically for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity [3]. This distinction is crucial: prescribing Ozempic for weight loss constitutes off-label use in the UK, whilst Wegovy is the only semaglutide formulation licensed for this indication.

Clinical Trial Evidence: STEP Programme vs SUSTAIN Trials

The SUSTAIN trials, which supported Ozempic's diabetes indication, also documented substantial weight loss as a secondary outcome. SUSTAIN 6, a cardiovascular outcomes trial, showed participants on Ozempic 1mg lost an average of 4.3kg, whilst those on 0.5mg lost 3.6kg over 104 weeks [5]. However, these trials enrolled patients with type 2 diabetes and cardiovascular risk factors, making direct comparison with the STEP programme's obesity-focused population methodologically problematic.

Importantly, the STEP trials used higher maintenance doses (2.4mg weekly for Wegovy) compared to Ozempic's maximum licensed dose of 2mg weekly for diabetes management. This dose-response relationship partly explains the greater weight loss observed with Wegovy in dedicated obesity trials, though individual patient responses vary considerably based on adherence, lifestyle factors, and metabolic characteristics [2][5].

STEP Trial Results for Wegovy

The STEP 1 trial enrolled 1,961 adults without diabetes and demonstrated that participants receiving Wegovy 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. More than one-third of Wegovy-treated participants lost 20% or more of their initial body weight, a threshold associated with significant cardiometabolic benefit. These results established Wegovy as the most effective pharmacological weight loss intervention studied in large-scale randomised controlled trials at the time of its approval.

Feature Ozempic Wegovy
Active Ingredient Semaglutide Semaglutide
MHRA Licensed Indication Type 2 diabetes Chronic weight management
Maximum Dose 2mg weekly 2.4mg weekly
Average Weight Loss (Clinical Trials) 3.6-4.3kg (SUSTAIN 6) 14.9% body weight (STEP 1)
Injection Frequency Once weekly Once weekly
Starting Price at Cured Pharmacy Not available for weight loss From £69.00

Dosing Protocols and Treatment Titration for Ozempic vs Wegovy

Wegovy follows a structured five-month titration schedule designed to minimise gastrointestinal side effects whilst reaching the therapeutic 2.4mg weekly maintenance dose. Patients begin with 0.25mg weekly for four weeks, then escalate through 0.5mg, 1mg, and 1.7mg doses at monthly intervals before reaching the target 2.4mg dose [3]. This gradual escalation allows the digestive system to adapt to semaglutide's effects on gastric motility.

Ozempic's titration differs based on its diabetes management focus. The typical protocol starts with 0.25mg weekly for four weeks (a dose not intended for glycaemic control but rather tolerability), then increases to 0.5mg weekly. If additional glycaemic control is required after at least four weeks, the dose may increase to 1mg weekly, with a maximum of 2mg weekly available for some patients [1]. UK prescribers determine appropriate dosing based on individual response and tolerability, with adjustments made during regular clinical reviews.

Side Effect Profiles and Safety Considerations

Serious but rare risks associated with semaglutide include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not confirmed in humans). The MHRA requires all semaglutide products to carry warnings about these risks, and UK prescribers must screen for contraindications including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1][3].

Patient education about expected side effects significantly improves treatment adherence. Our superintendent pharmacist Tarun Kumar emphasises that staying well-hydrated, eating smaller portions, and avoiding high-fat meals can substantially reduce gastrointestinal discomfort during the initial treatment weeks. All patients receiving semaglutide through Cured Pharmacy receive comprehensive guidance on managing potential side effects and recognising symptoms requiring medical attention.

Common Adverse Effects

Both medications share similar side effect profiles due to their identical active ingredient. The most frequently reported adverse effects include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, particularly during dose escalation phases [2][3]. In the STEP 1 trial, 74% of Wegovy participants experienced gastrointestinal adverse events, though most were mild to moderate in severity and diminished over time. Approximately 4.5% of participants discontinued treatment due to gastrointestinal side effects.

Cost Considerations and UK Availability

Wegovy is available through Cured Pharmacy with transparent upfront pricing, allowing UK patients to understand treatment costs before completing their clinical consultation. Our registered prescribers assess eligibility based on MHRA-approved criteria, including BMI thresholds and weight-related health conditions. All pricing is clearly displayed prior to consultation, with no hidden fees or subscription requirements.

NHS availability for weight management medications remains limited, with access typically restricted to specialist weight management services in specific clinical circumstances. NICE recommends considering pharmacological interventions only after comprehensive lifestyle programmes, and local integrated care boards may have additional prescribing restrictions based on commissioning decisions [4]. Private prescription services like Cured Pharmacy offer an alternative pathway for eligible patients who meet clinical criteria but face extended NHS waiting times or local prescribing limitations.

Treatment duration varies based on individual response and clinical goals. NICE guidance suggests reviewing weight loss medications after 12 months, with continuation dependent upon achieving meaningful weight reduction (typically defined as 5% or more of initial body weight) and ongoing commitment to lifestyle modification [4]. UK prescribers must balance treatment efficacy against cost-effectiveness and patient-specific factors when recommending long-term pharmacological weight management strategies.

Scientific References

  1. Novo Nordisk. (2023). Ozempic (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/9817
  2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
  3. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799
  4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875
  5. Marso, S. P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy and Ozempic are prescription-only medicines containing semaglutide. Individual results may vary. Weight loss outcomes depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Can I use Ozempic for weight loss in the UK?
Ozempic is licensed only for type 2 diabetes treatment in the UK. Prescribing it for weight loss constitutes off-label use, whilst Wegovy holds specific MHRA approval for chronic weight management in eligible patients.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide, but Wegovy is specifically licensed for weight management at doses up to 2.4mg weekly, whilst Ozempic is approved for diabetes treatment with a maximum 2mg weekly dose. Clinical trial programmes and regulatory indications differ significantly.
How much weight can I lose with Wegovy compared to Ozempic?
In the STEP 1 trial, Wegovy participants lost an average of 14.9% of their body weight over 68 weeks. Ozempic trials focused on diabetes management showed more modest weight loss of 3.6-4.3kg, though direct comparison is limited by different study populations and endpoints.
Is Wegovy more effective than Ozempic for weight loss?
Clinical evidence suggests Wegovy produces greater weight loss, partly due to its higher maximum dose (2.4mg vs 2mg) and specific development for obesity treatment. However, individual responses vary, and UK prescribers assess suitability based on licensed indications and patient-specific factors.
Do Ozempic and Wegovy have the same side effects?
Yes, both medications share similar side effect profiles including nausea, diarrhoea, vomiting, and abdominal discomfort, as they contain the same active ingredient. Severity and duration of side effects vary between individuals and typically diminish during continued treatment.
Can I switch from Ozempic to Wegovy?
Switching between semaglutide formulations requires clinical assessment by a UK prescriber, who will consider your current dose, treatment response, and eligibility for Wegovy's weight management indication. Dose adjustments and monitoring protocols may differ between the two medications.
How long does Wegovy take to work for weight loss?
Most patients begin noticing appetite reduction within the first few weeks of treatment. Significant weight loss typically becomes apparent after reaching higher maintenance doses, with the STEP trials demonstrating progressive weight reduction over 68 weeks of continued treatment.
Is Wegovy available on the NHS for weight loss?
NHS access to Wegovy remains limited, typically through specialist weight management services for patients meeting specific clinical criteria outlined in NICE guidance. Many eligible UK patients access treatment through registered private pharmacy services like Cured Pharmacy following clinical assessment.
What is the main difference between Ozempic and Wegovy for weight loss in the UK?
Both contain semaglutide, but Wegovy is licensed specifically for weight loss at higher doses (up to 2.4mg), while Ozempic is licensed for type 2 diabetes at lower doses. Cured Pharmacy offers Wegovy with full clinical support for weight management, ensuring you get the correct licensed treatment for your needs.
Can I switch from Ozempic to Wegovy for weight loss in the UK?
Yes, many patients switch from Ozempic to Wegovy under medical guidance to access higher doses licensed for weight loss. Cured Pharmacy's prescribers can assess your current dose and create a safe transition plan, ensuring continuity of your weight loss journey with the appropriate licensed medication.
Is Wegovy more expensive than Ozempic in the UK?
Wegovy starting doses begin at £69 at Cured Pharmacy, with prices increasing at higher doses for weight loss. Ozempic is typically prescribed for diabetes and may have different pricing structures. Cured Pharmacy offers transparent pricing and £20 off your first Wegovy order with code WEIGHTLOSSNEW.
Why is Wegovy better than Ozempic for UK weight loss goals?
Wegovy is clinically trialled and licensed specifically for chronic weight management, with dosing optimised for weight loss up to 2.4mg. While Ozempic contains the same active ingredient, it is licensed for diabetes at lower doses. Cured Pharmacy ensures you receive Wegovy with proper weight loss clinical protocols and ongoing support.
Can I get Wegovy on the NHS or is private cheaper in the UK?
NHS Wegovy access is extremely limited with strict eligibility criteria and long waiting lists. Private providers like Cured Pharmacy offer faster access from £69, with same-day prescriber consultations and next-day delivery options, making private treatment more accessible for most UK patients seeking weight loss support.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 17 July 2026